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https://doi.org/10.1016/j.cub.2020.10.026SUMMARYOrganelles of the endomembrane system maintain their identity and integrity during growth or stress condi-
tions by homeostaticmechanisms that regulatemembrane flux andbiogenesis. At lysosomes and endosomes,
the Fab1 lipid kinase complex and the nutrient-regulated target of rapamycin complex 1 (TORC1) control the
integrity of the endolysosomal homeostasis and cellular metabolism. Both complexes are functionally con-
nected as Fab1-dependent generation of PI(3,5)P2 supports TORC1 activity. Here, we identify Fab1 as a target
of TORC1 on signaling endosomes, which are distinct from multivesicular bodies, and provide mechanistic
insight into their crosstalk. Accordingly, TORC1 can phosphorylate Fab1 proximal to its PI3P-interacting
FYVE domain, which causes Fab1 to shift to signaling endosomes, where it generates PI(3,5)P2. This, in
turn, regulates (1) vacuole morphology, (2) recruitment of TORC1 and the TORC1-regulatory Rag GTPase-con-
taining EGO complex to signaling endosomes, and (3) TORC1 activity. Thus, our study unravels a regulatory
feedback loop between TORC1 and the Fab1 complex that controls signaling at endolysosomes.INTRODUCTION
Eukaryotic organelles differ in the lipid and protein composition
of their surfaces and thus maintain a unique identity. Along the
endomembrane system, proteins are transported by vesicles
that are generated at the donor compartment and fuse with an
acceptor organelle. Despite this active transport between organ-
elles, each organelle maintains its identity. Apart from the fusion
and fission machineries involved in each transport step, organ-
elle-specific phosphatidylinositol phosphates (PIPs) are impor-
tantmarkers that contribute to the identity of distinct organelles.1
PIPs are phosphorylated derivatives of phosphatidylinositol (PI),
which can bemodified at three positions by specific lipid kinases
and phosphatases to generate seven distinct isoforms.2 Organ-
elle-specific PIPs are proposed to recruit specific proteins to
their surface, which then have decisive roles in cell signaling,
membrane trafficking, and lipid metabolism. Proteins may
recognize not only PIPs but additionally also membrane-associ-
ated proteins, which increases the specificity of theirCurrent Biology 31, 297–309, Jan
This is an open access article undlocalization—a mechanism termed coincidence detection.
Consequently, PIP production and turnover is tightly controlled
to maintain organelle identity.2
Within the endosomal system, proteins and lipids are trans-
ported either from the plasmamembrane or Golgi to the early en-
dosome. These endosomes then undergo maturation and sort-
ing processes, whereby a number of membrane proteins are
sorted into intraluminal vesicles by the endosomal sorting com-
plexes required for transport (ESCRT) machinery, whereas
others are recycled with the support of retromer complexes.
ESCRTs function in consecutively acting complexes on endo-
somes. Early acting complexes (0–II) recognize ubiquitinated
membrane proteins, whereas ESCRT-III and the interacting
ATPase Vps4 corral the proteins and promote formation of intra-
luminal vesicles.3 Mature late endosomes, also called multive-
sicular bodies (MVBs), eventually fuse with the lysosome.4 Two
PIPs, phosphatidylinositol-3-phosphate (PI3P) and phosphati-
dylinositol-3,5-bisphosphate (PI(3,5)P2), are essential for endo-
somal and lysosomal biogenesis. The Vps34 kinase complex IIuary 25, 2021 ª 2020 The Author(s). Published by Elsevier Inc. 297
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESS Articleproduces PI3P at endosomes, which is also found at vacuoles in
yeast (or lysosomes in metazoan cells).2,5 Subunits of both the
retromer and ESCRT complexes have PX and FYVE domains,
which bind specifically to PI3P and thus endosomes.6 PI3P
can be further phosphorylated to the low abundant PI(3,5)P2,
which is strongly upregulated during osmotic stress.7 In yeast,
osmotic stress results in fragmentation of the vacuole tomaintain
organelle integrity.8 Vacuolar fragmentation is also required for
the inheritance of vacuoles to daughter cells, and also here
PI(3,5)P2 levels play an important regulatory role.
9 Moreover,
nutrient supply as an activator of TORC1 also affects vacuole
fragmentation,10 though the TORC1 substrate(s) that is relevant
for this process remains unknown.
The PI3P 5-kinase Fab1, called PIKfyve in metazoans, is part
of a multisubunit complex, which includes the PI(3,5)P2 phos-
phatase Fig4, the scaffold protein Vac14, and Atg18.1,11–13
Fab1, Fig4, and Vac14 form the core of the complex.11,13,14
Full Fab1 activity in yeast also requires the vacuolar membrane
protein Vac715 and is controlled by Atg18.16,17 Consequently,
mutants lacking either Fab1, Vac7, or Vac14 exhibit very large
vacuoles and defects in protein sorting at endosomes and vac-
uoles.18–21 Likewise, inactivation of metazoan PIKfyve affects
PI(3,5)P2 production and lysosomal biogenesis and homeosta-
sis.1,22–24 In humans, suchmutations result in devastating neuro-
degenerative diseases, demonstrating that PI(3,5)P2 levels need
to be tightly controlled.25–28
The identification of PI(3,5)P2 effectors starts to shed light on
the role of this lipid in lysosomal biogenesis and homeostasis.
In yeast, the most prominent interactor is Atg18,16 which can
directly induce membrane fragmentation.29 Additional PI(3,5)
P2-interactors include lysosomal ion channels, the vacuolar
ATPase, and a subunit of the lysosomal target of rapamycin
complex 1 (TORC1).1,7,12,23,30–33
TORC1 was initially identified in yeast, and is conserved
across eukaryotic species.34 It consists of the protein kinases
Tor1 or Tor2 (mTOR in humans), Kog1/Raptor, Lst8/mLST8,
and the yeast-specific subunit Tco89.34 TORC1 is a cellular
pacemaker that promotes anabolic processes and growth. Nu-
trients, particularly amino acids, are required for TORC1 activ-
ity.35 Amino acids are sensed by another conserved lysosomal
complex, the Rag GTPase-containing EGO complex (Ragula-
tor-Rag complex in metazoans) and its regulators, such as the
SEACIT and SEACAT complexes (GATOR1 and 2 in meta-
zoans).36–38 The FYVE domain-containing yeast protein Pib2
represents another amino acid-sensing branch that regulates
TORC1, although its conservation in higher eukaryotes has not
been demonstrated.39–43 Recent data suggest that yeast
TORC1 also responds to glucose as it oligomerizes upon
glucose starvation in structures known as TORC1 bodies or TO-
ROIDs, in which TORC1 is inactive.44,45 Inactivation of TORC1 in
turn activates catabolic processes including autophagy, high-
lighting its central function in growth control.
The EGO complex and TORC1 localize to a special endosomal
population in yeast that we coined ‘‘signaling endosomes.’’46,47
Suchendosomesaredistinct frompreviouslydescribedmetazoan
endosomes involved in signaling via, for instance, the epidermal
growth factor.48 Ivy1, an effector of the vacuolar Rab GTPase
Ypt749 and inhibitor of the Fab1 complex50 colocalizes with Fab1
and the EGO complex to dots proximal to the vacuole.49,51298 Current Biology 31, 297–309, January 25, 2021We now present evidence that signaling endosomes have a
key function in endosome and vacuole membrane homeostasis.
Ivy1, Fab1, the EGOcomplex, and TORC1 all localize to signaling
endosomes in addition to their vacuolar localization. We uncover
that Fab1 is a TORC1 substrate and that phosphorylation of
Fab1 shifts not only the primary localization of the Fab1 complex
from vacuoles to signaling endosomes but also of TORC1. This in
turn results in a local PI(3,5)P2 accumulation at signaling endo-
somes and altered TORC1 activity. Our data highlight a novel
feedback loop between a lipid kinase and themetabolically regu-
lated TORC1 at endomembranes.
RESULTS
TORC1 and Fab1 Localize to Signaling Endosomes and
Interact with Each Other
Both Ivy1, as a Fab1 inhibitor, and TORC1 localize to the vacuole
and distinct dots.49–51 As Ivy1 localization was unaffected by
ESCRT-III deletions,49 we previously discarded the possibility
that Ivy1 resides also on endosomes. However, it was recently
shown that a second population of endosomes exists, which
contains an endosomal pool of TORC1 and the EGO complex.52
As Ivy1 also strongly colocalizes with EGO components in dots
proximal to the vacuole,49 we wondered if all proteins, including
TORC1 and Fab1, function together on signaling endosomes.
To ask if Ivy1, Fab1, and TORC1 are present on these endo-
somes, we analyzed the localization of GFP-tagged Ivy1 relative
to mCherry-tagged Kog1 (a subunit of TORC1), Vps4 (the disas-
sembling ATPase of ESCRT-III proteins at MVBs), and Vps8 (a
subunit of endosomal CORVET, which binds the Rab5-like
Vps21 protein). Indeed, we observed that a fraction of Ivy1 colo-
calized with Kog1 and Vps8 positive dots but not with dots pos-
itive for Vps4 (Figures 1A and 1B). This suggests that a significant
portion of Ivy1 is present on signaling endosome, but not MVBs,
together with the endosomal TORC1.
We then analyzed if Fab1 is also present on these signaling en-
dosomes with Ivy1 and TORC1. Indeed, a significant amount of
mNeonGreen-tagged Fab1 colocalized with mCherry-tagged
Kog1, Ivy1, and Vps8 in dots proximal to the vacuole (Figures
1C–1E). Fab1 was, however, also present on Vps4-positive
MVBs, and thus has a broader distribution (Figures 1C–1E).
To determine if TORC1 and Fab1 contact each other on
signaling endosomes, we added the C-terminal half of the Venus
fluorescence protein to Fab1 (VC) and the N-terminal half to
Kog1 (VN). If close enough, both halves (VN and VC) will interact
and form a fluorophore. We detected fluorescent dots proximal
to vacuoles (Figure 1F), which colocalized with Vps8 and Ivy1
(Figures 1G and 1H), and this signal was specific as Fab1-VC
alone or co-expression with Vac8-VN did not produce any signal
(Figure 1F).
Overall, our data reveal that Ivy1, Fab1, and TORC1 localize
both to vacuoles and to signaling endosomes (Figure 1E), where
Fab1 and TORC1 are in close proximity.
Fab1 Is Phosphorylated by TORC1
As Fab1 and TORC1 are in close proximity on signaling endo-
somes, we asked whether Fab1 is a direct target of TORC1
and thus conducted two lines of independent assays. As a first







Figure 1. A Pool of Fab1 Complex Localizes
with TORC1 to Signaling Endosomes
(A) Ivy1 is a marker of signaling endosomes. Cells
expressing Ivy1-mGFP and mCherry-Kog1 (under
the ADH1 promoter), Vps4-3xHA-mCherry, or
Vps8-mCherry were imaged by fluorescence mi-
croscopy. Scale bar, 5 mm. Scale bar (inset), 1 mm.
(B) Quantification of colocalization of Ivy1-positive
dots with Kog1, Vps4, or Vps8 dots. The per-
centage of colocalization normalized to the num-
ber of Ivy1-dots was plotted. At least 150 cells and
60 Ivy1 dots were counted from three independent
experiments. Results are means ± standard devi-
ation (SD). Significance was determined with a
two-tailed Student’s t test (****p < 0.0001).
(C) Fab1 localizes to the vacuole, signaling endo-
somes, and MVBs. Cells expressing Fab1-
mNeonGreen andmCherry-Kog1 (under theADH1
promoter), Vps4-3xHA-mCherry, Vps8-mCherry,
or Ivy1-mCherry were imaged by fluorescence
microscopy. Scale bar, 5 mm. Scale bar (inset),
1 mm.
(D) Quantification of colocalization of Fab1-posi-
tive dots with Kog1, Vps4, Vps8, or Ivy1 dots. Fab1
dots colocalizing with mCherry signal were coun-
ted and plotted as percent of the total number of
Fab1 dots. At least 150 cells and 60 Fab1 dots
were counted from three independent experi-
ments. Results are means ± SD; ns, no significant
difference.
(E) Summary of Fab1 localization in yeast cells.
The table summarizes markers of signaling endo-
somes, MVBs, and vacuoles.
(F) Proximity of TORC1 and Fab1 by bimolecular
fluorescence complementation assay. Fab1 was
C-terminally tagged with the C-terminal half of the
Venus fluorescence protein (VC), and Kog1 was
N-terminally tagged with N-terminal half (VN) un-
der the control of the CET1 promoter. Cells were
monitored by fluorescencemicroscopy. Scale bar,
5 mm.
(G) Fab1 and TORC1 interact at signaling endo-
somes. Cells co-expressing VN-Kog1 and Fab1-
VC were co-expressed with Vps8-mkate (top) or Ivy1-mkate (bottom) and stained with CMAC. Analysis was done as in (A). Scale bar, 5 mm.
(H) Quantification of colocalization between Fab1-TORC1 dots and Vps8 or Ivy1 dots. The percentage of colocalization was calculated by counting colocalization
dots divided by the total Fab1-VC VN-Kog1 dots. At least 150 cells and 50 dots were counted in each of the three independent experiments. Results are means ±
SD; ns, no significant difference.
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and identified serine residue 208 (Ser208) in Fab1 as a potential
target of TORC1 in vivo, whereas other sites in Fab1 (Ser125
and Ser155) were unaffected. The same assay also identified
the known bona fide TORC1 target residue Thr723 in Sch9 (Fig-
ure 2A).53 Ser208 is located next to the PI3P interacting FYVE
domain in Fab1 (residues 230–320; Figures 2A and 2B). In a sec-
ond approach, we subjected Fab1 to in vitro TORC1 kinase as-
says in the absence or presence of wortmannin, a potent
TORC1 inhibitor.53,54 To this end, we expressed (in bacteria)
and purified four overlapping His-tagged Fab1 fragments that
covered the entire length of the protein and incubated them
with purified TORC1 (from yeast) and radioactive [32P]-ATP (Fig-
ure 2C). Autophosphorylation of Tco89 by TORC1 served as
positive control for TORC1 activity. Of the four fragments,
TORC1 only phosphorylated the N-terminal Fab11–600 construct
in the absence, but not in the presence, of wortmannin(Figure 2C). We confirmed via mass spectrometry that Fab11–
600 was phosphorylated by TORC1 at Ser208, Ser204, and
Ser210 (Figure 2A). Recombinant variants of Fab11–600, in which
these three residues alone (3A) or combined with the adjacent
Ser201 and Thr206 (5A), weremutated to alanines (Ala) (Figure 2B),
were only marginally phosphorylated by TORC1 (Figure 2D).
Based on these results, we conclude that TORC1 phosphory-
lates Fab1 at mainly Ser204, Ser208, and Ser210.
Fab1 Phosphorylation Affects Vacuole Morphology and
EGO Localization
To determine whether Fab1 phosphorylation by TORC1 affected
endosome and vacuole biogenesis, we generated (using
CRISPR/Cas9 gene editing) fab16A and fab16D mutant alleles.
Here, the entire cluster of Ser/Thr residues between Ser202 and
Ser210 was replaced by either Ala or phosphomimetic aspartates





Figure 2. TORC1 Phosphorylates Fab1
(A) TORC1 phosphorylates multiple residues within the N-terminal part of
Fab1. The table shows the rapamycin sensitivity of phosphorylation of Ser125,
Ser155, Ser208 on Fab1, and Thr723 of Sch9 in vivo, as detected by SILAC mass
spectrometric analysis, and the identification of the phosphopeptide con-
taining phosphorylated Ser125, Ser155, Ser204, Ser208, and Ser210 detected on
purified Fab11–600 following in vitro phosphorylation by TORC1. Wortmannin
(WM) was used to inhibit TORC1 in vitro (see STAR Methods). PEP, posterior
error probability; the smaller the number, the better is the hit. >100 implies that
the phosphorylation levels of the respective amino acid residues were at least
two orders of magnitude higher in samples treated with TORC1 when
compared to the ones treated with TORC1 in the presence of WM.
(B) Model of the Fab1 sequence including the potential TORC1 target phos-
phosites. The Fab1 domains are indicated as FYVE domain (230–320), chap-
eronin containing TCP1 (CCT) domain (766–1039), conserved cysteine rich
(CCR) domain (1181–1500), and kinase domain (1900–2266). The region be-
tween residues 201 and 210 is highlighted with the identified Ser204, Ser208, and
Ser210 shown in blue, the corresponding mutant alleles are indicated in red.
(C) TORC1 kinase predominantly phosphorylates the N-terminal part (en-





Fab11760–2278) were subjected to in vitro phosphorylation by TORC1 (purified
from yeast) in the absence () or presence (+) of the TORC1 inhibitor WM (see
STAR Methods). Representative SYPRO Ruby staining and autoradiography
(32P) blots are shown.
(D) Mutation of identified phosphosites strongly impairs the in vitro Fab1
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ArticlemNeonGreen variants to trace their localization. While the wild-
type Fab1 and Fab16A protein localized mainly to round, wild-
type-like vacuoles and to some dots, Fab16D was enriched in
dot-like structures around fragmented vacuoles (Figures 3A
and 3B), which we identified as endosomes, as they colocalize
with the endosomal Vps8 protein (Figure 6A). Interestingly,
mCherry-tagged Ivy1 and the TORC1 subunit Kog1 showed a
similar subcellular distribution pattern as Fab1, Fab16A, or
Fab16D in each of the strains expressing the respective Fab1
allele (Figures 3C–3E). Moreover, the EGO complex subunit
Ego1 also colocalized with Kog1 in wild type, fab16A, and
fab16D mutant cells (Figure 3D). Fab16D, however, did not coloc-
alize with the MVB-marker Vps4 (Figures 3F and 3G; see inset),
indicating that a fraction of Fab16D accumulates on signaling en-
dosomes. Finally, Fab16D-expressing cells exhibited a
significantly higher number of Ivy1, Ego1, and Kog1 dots next
to vacuoles than wild-type cells or, even more, than Fab16A-ex-
pressing cells (Figure 3H). These data indicate that Fab1 phos-
phorylation results in a significant shift of Fab1, TORC1, and
the EGO complex from their vacuole localization to signaling en-
dosomes. If, however, Fab1 cannot be phosphorylated, TORC1
and the EGO complex seem to become more confined to the
vacuole, though some dot-like structures remain.
We next asked if the phosphomimetic fab16D mutant, which
showed an aberrant vacuole morphology, has defects in vacu-
ole biogenesis or endolysosomal protein trafficking. As the
vacuolar fragmentation observed in fab16D cells can be the
result of either increased fission or impaired fusion,29 we
stained vacuoles with FM4-64 and subjected cells to a brief in-
cubation in water, which promotes vacuole fusion. Under these
circumstances, the vacuoles in the fab16D strain looked like the
ones in wild type, suggesting that vacuole fragmentation in the
fab16D mutant is not due to defects in fusion (Figure S1A). Vac-
uole fragmentation often indicates defects in vacuole protein
sorting and biogenesis, and fab1D cells also have an endoso-
mal protein sorting defect.21 Therefore, we tested the traf-
ficking of selected cargo proteins from the Golgi or plasma
membrane to the vacuole. Sorting of carboxypeptidase Y
(CPY) to vacuoles as monitored by its abundance in cells was
functional in wild-type and fab1 mutants but defective if vacu-
ole biogenesis was impaired by deleting the HOPS subunit
Vps39 (Figure S1B). Likewise, trafficking of the plasma mem-
brane localized dicarboxylic acid transporter Dip5 or carboxy-
peptidase S (Cps1) via MVBs into the vacuole lumen was unaf-
fected in fab1 mutants but impaired if the ESCRT protein Vps4
was lacking (Figures S1C and S1D). Similarly, a synthetic AP-3
cargo55 was sorted efficiently to vacuoles in both fab1 mutants
but was missorted in a mutant lacking the AP-3 subunit Apl5
(Figure S1E). We thus conclude that phosphorylation of Fab1
results in both vacuole fragmentation and redistribution of
Fab1 as well as the EGO complex and TORC1 components to
signaling endosomes. However, it does not impair overall
endocytosis or MVB biogenesis.or not, the Ser-to-Ala mutations at positions Ser204, Ser208, and Ser210 (3A), or
at Ser203, Ser204, Ser206, Ser208, and Ser210 (5A) were subjected to in vitro
phosphorylation by TORC1 (purified from yeast) in the absence () or presence
(+) of the TORC1 inhibitor WM. Representative SYPRO Ruby staining and






Figure 3. Phosphorylation Mutants of Fab1
Affect Fab1 Localization at Vacuoles and
Endosomes
(A) Localization of Fab1 phosphomutants in cells.
Fab1 was C-terminally tagged with mNeonGreen,
and the Fab16A and Fab16D mutations were
generated in the genome by CRISPR/Cas9 (see
STARMethods). Fab1 localization relative to FM4-
64 stained vacuolar membranes was analyzed by
fluorescence microscopy. Scale bar, 5 mm. Scale
bar (inset), 1 mm.
(B) Quantification of vacuole morphology from (A).
At least 200 cells were counted from three inde-
pendent experiments. Results are means ± SD.
Significance was determined with a two-tailed
Student’s t test (***p < 0.001; **p < 0.01; *p < 0.05).
(C) Kog1 localization in fab1 mutants. Cells ex-
pressing Fab1-mNeonGreen with mCherry-Kog1
were analyzed by fluorescence microscopy. Scale
bar, 5 mm. Scale bar (inset), 1 mm.
(D) Localization of Ego1 and Kog1 proteins in fab1
mutants. Ego1 was tagged C-terminally with GFP,
and Kog1 was tagged N-terminally with mCherry
under the control of the ADH1 promoter. All im-
ages were taken by fluorescence microscopy.
Scale bar, 5 mm. Scale bar (inset), 1 mm.
(E and F) Ivy1 and Vps4 localization in fab1 mu-
tants. Ivy1-mCherry (E) or Vps4-3HA-mCherry (F)
was co-expressed with Fab1-mNeonGreen, and
analysis was as in (C).
(G) Quantification of colocalization between Fab1
and Kog1, Vps4, or Ivy1 dots in fab1 mutants.
Fab1 dots colocalizing with mCherry signal were
counted and plotted as percent of total number of
Fab1 dots. At least 60 Fab1 dots were counted in
each of the three independent experiments. Re-
sults are means ± SD. Significance was deter-
mined with a two-tailed Student’s t test (**p < 0.01;
*p < 0.05; ns, no significant difference).
(H) Quantification of dot-like structures in (C–E). At
least 100 cells were counted from three indepen-
dent experiments. Results are mean ± SD. Sig-
nificance was determined with a two-tailed Stu-
dent’s t test (****p < 0.0001).
See also Figure S1.
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TORC1 requires PI(3,5)P2 on membranes for its activity,
31 yet
TORC1 also phosphorylates Fab1 (Figure 2). We therefore asked
if phosphorylation of Fab1 as probed by our fab1 alleles would
also affect TORC1 activity.
To test for TORC1 activity, we used growth on rapamycin as a
readout. Strikingly, we observed that cells carrying fab16D grewas
poorly as tor1D cells. In contrast, cells with fab16A were slightly
more resistant to rapamycin than wild-type cells when grown at
either 30C or 37C (Figure 4A). All cells grew similarly well in
the absence of rapamycin. To reveal if tor1D and fab16D strains
differ, we compared their sensitivity on plates containing
increasing amounts of rapamycin and observed that tor1D cells
already showed growth deficiency at 1 ng/mL, whereas fab16D
strains began to show this phenotype at 4 ng/mL (Figure S2A).
This indicates that Fab1 mutants modulate TORC1 activity rather
than abolish it. Whenwe transformed these cells with a vector en-
coding wild-type Fab1, we observed rescue of the growthphenotypes on rapamycin (Figure 4B). This indicates that the mu-
tations did not cause secondary defects within the genome and
that the Fab1 mutant alleles are not dominant over the wild-type
allele. We conclude that Fab1 phosphorylation also affects
TORC1 activity.
To determine if Fab1 phosphorylation specifically affects
TORC1 activity on endosomes or vacuoles (Figure 4C), we used
established TORC1 activity reporters that specifically localize to
endosomes (ET) or to vacuoles (VT)47,52 (see STAR Methods; Fig-
ure 4D). We determined TORC1 activity by decorating blots with a
phospho-specific antibody to Sch9, which recognizes phosphor-
ylated Sch9-Thr737, a bona fide TORC1 target residue in yeast
(Figure 4C). By shifting cells from proline to glutamine, TORC1 is
strongly activated,57 as indicated by a strong increase in the phos-
phorylation signal of both reporters (ET and VT) and endogenous
Sch9 (Figure 4C). Both ET and VT reporters behaved similarly in
the wild type and fab16A mutant. In contrast, their phosphoryla-





Figure 4. Fab1 Mutations Affect TORC1
Activity
(A) Growth phenotype of fab1 mutants on rapa-
mycin. The indicated strains were grown to
exponential growth phase in SDC+all medium,
diluted sequentially 10-fold, spotted onto plates
containing SDC+all with or without 4 ng/mL ra-
pamycin, and grown at 30C or 37C for 2–
5 days.
(B) Complementation of fab1 mutants. The indi-
cated cells were transformed with an empty
vector (EV) or a plasmid encoding wild-type Fab1
(pFAB1). The same spotting assay was done as in
(A) on the indicated plates.
(C) Expression of the Fab16D allele impairs
TORC1 activation at both endosomes and vac-
uoles. FAB1-mNG, fab1-mNG6A, and fab1-
mNG6D strains were transformed with ET/VT re-
porters, grown to mid-log phase in proline me-
dium (Pro), and stimulated (+) or not () with 3mM
glutamine (Gln) for 2 min. Proteins were ex-
tracted, resolved by SDS-PAGE, and the phos-
phorylation level of ET, VT, and endogenous Sch9
were detected by immunoblotting using phos-
pho-specific anti-Sch9-pThr737 antibodies. Input
levels of ET/VT and endogenous Sch9 were de-
tected with anti-GFP and anti-Sch9 antibodies,
respectively. Different exposures are shown to
visualize the effects on ET and VT. The asterisks
beside the western blot indicate a nonspecific
signal. Significance was determined with a two-
tailed Student’s t test (***p < 0.001; *p < 0.05; ns,
no significant difference)
(D) Localization of GFP-tagged endosomal (ET)
and vacuolar TORC1 (VT) reporters. Wild-type,
fab16A, and fab16D cells were transformed either
with ET or VT and grown to mid-log phase and
analyzed by fluorescence microscopy. Scale bar,
5 mm.
(E) Effect of hyperactive TORC1 on growth phe-
notypes of fab1mutants. A plasmid encoding the
hyperactive Tor1I1954V allele56 or the empty vec-
tor (EV) were transformed into the indicated
strains. The spotting assay was done as in (A) on
the indicated plates.
See also Figure S2.
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Fab1 causes reduced TORC1 activity. Next, we asked if the
expression of the hyperactive Tor1I1954V allele56 could suppress
this phenotype and observed that it generally conferred some
resistance to rapamycin in all strains. Nevertheless, the fab16D
strain remained significantly more sensitive to rapamycin when
compared to the respective fab16A and wild-type strains even in
the presence of the Tor1I1954V allele (Figure 4E). This suggests
that fab16Dmutant is dominant over known hyperactivemutant al-
leles of tor1. Thus, phosphorylation of Fab1 seems to control
TORC1 activity possibly by regulating PI(3,5)P2 synthesis.
TORC1 Controls Local Synthesis of PI(3,5)P2 at the
Signaling Endosome
Our data so far imply that TORC1-mediated phosphorylation
shifts a significant amount of Fab1 to signaling endosomes. As302 Current Biology 31, 297–309, January 25, 2021Fab1 is a lipid kinase, we wondered if Fab1 would then generate
PI(3,5)P2 at signaling endosomes. To determine the local PI(3,5)
P2 pools, we searched for a suitable reporter. The S6Kinase ho-
molog Sch9 is a TORC1 target that localizes to vacuoles in a
Fab1- and thus PI(3,5)P2-dependent manner, and its N-terminal
region (residues 1–390) directly interacts with PI(3,5)P2
in vitro.31.To identify a minimal PI(3,5)P2-interacting fragment
within Sch9, we localized several truncations in wild-type cells
as GFP-fusion proteins. Whereas full-length GFP-Sch9 and an
internally truncated GFP-Sch9D184–397 protein were found in
part at the vacuole, all fragments lacking the first 183 residues
were cytosolic (Figure 5A). However, GFP-tagged Sch91–397,
and to a greater extent Sch91–183, localized strongly to periva-
cuolar dots and faintly to vacuoles (Figure 5B). This dot localiza-
tion was completely lost in mutants lacking Fab1, Vac7 or Vac14,








Figure 5. PI(3,5)P2 Production Occurs at
Signaling Endosomes
(A–C) Identification of a Sch9 fragment as a PI(3,5)
P2 specific reporter.
(A and B) Mapping of Sch9 localization. GFP-
tagged Sch9 fragments were expressed in cells,
grown to mid-log phase, and localized by fluo-
rescence microscopy. Scale bar, 5 mm.
(C) Localization of the Sch9 fragment, Sch91–183, in
mutants of the Fab1 complex. A vector encoding
mCherry-tagged Sch91–183 was expressed in wild-
type, fab1D, vac7D, and vac14D cells that were
grown to mid-log phase, and Sch91–183 was
localized by fluorescence microscopy. Scale bar,
5 mm.
(D and E) Recombinant Sch91–183 binds prefer-
entially to PI(3,5)P2. Liposomes (see STAR
Methods) containing the indicated amounts of
PI(3,5)P2 and PI3P were incubated with purified
His-tagged Sch91–183 and then separated by
centrifugation into pellet and supernatant (sup)
fractions. Proteins were precipitated by TCA,
washed with acetone, dissolved in sample buffer,
and resolved on SDS gels and blotted. Western
blots were decorated with anti-His antibodies. In
(D), liposomes contained 10% PIPs (n = 4), and in
(E), different concentrations on liposomes were
compared. For details see STAR Methods. Sig-
nificance was determined with a two-tailed Stu-
dent’s t test (**p < 0.01; *p < 0.05; ns, no significant
difference).
(F) Localization of Sch91–183 relative to Tor1. GFP-
Tor1 was expressed together with mCherry-tag-
ged Sch91–183 and analyzed as before.
(G) Localization of Sch91–183 in fab1mutants. Cells
expressing Fab1-mNeonGreen and correspond-
ing mutants (Figure 3A) were transformed with a
plasmid encoding mCherry-tagged Sch91–183 and
analyzed as before. Quantification of Sch9 foci/
cell is shown below. At least 80 cells were
analyzed. Significance was determined with a
two-tailed Student’s t test (**p < 0.01; *p < 0.05; ns,
no significant difference).
(H) Effect of TORC1 localization on Sch9 dot for-
mation. tor1D cells were transformed with the
indicated plasmids and GFP-tagged Sch91–183
and analyzed by fluorescence microscopy. For
quantification, at least 100 cells were analyzed.
(I) Localization of mCherry-Sch91–183 in tor1D330-
3GFP cells, in which Tor1 is almost exclusively
localized on vacuolar membranes.47,58 For quan-
tification, at least 100 cells were analyzed. Signif-
icancewas determinedwith a two-tailed Student’s
t test (**p < 0.01; *p < 0.05; ns, no significant dif-
ference).
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OPEN ACCESSArticle(Figure 5C). Of note, Sch91–183 exclusively decorated vacuoles in
atg18D cells, suggesting that Atg18 is required to shift PI(3,5)P2
synthesis from vacuoles to perivacuolar dots, which will be fol-
lowed up elsewhere.
To confirm the specificity of our probe, we isolated recombi-
nant Sch91–183 from bacteria and incubated the protein with lipo-
somes containing PI3P or PI(3,5)P2 and separated liposomes
from proteins by centrifugation. At 10 mol% PI-lipids (Figure 5D),
but even more so at lower concentrations, Sch91–183 stronglyaccumulated in the pellet fraction of liposomes carrying PI(3,5)
P2 (Figure 5E). We therefore used Sch9
1–183 in further experi-
ments as a reporter of local PI(3,5)P2 levels at vacuoles and
endosomes.
To determine if increased PI(3,5)P2 levels are present at
signaling endosomes, we analyzed the localization of mCherry-
tagged Sch91–183 relative to GFP-Tor1, which is also present
on signaling endosomes.47 Indeed, we found both GFP-Tor1
and mCherry-tagged Sch91–183 in the same dot-like structureCurrent Biology 31, 297–309, January 25, 2021 303
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OPEN ACCESS Article(Figure 5F). A pool of Fab1-GFP was likewise found in mCherry-
Sch91–183 positive dots in wild-type cells. These Sch91–183-pos-
itive dots increased in size in the fab16Dmutant but were reduced
in the fab16A mutant (Figure 5G), suggesting that phosphoryla-
tion of Fab1 determines also local synthesis of PI(3,5)P2 at the
signaling endosome.
As TORC1-mediated phosphorylation results in Fab1 accu-
mulation at signaling endosomes, we next asked whether
TORC1 localization also affects endosomal PI(3,5)P2 levels. To
alter TORC1 localization, we fused TORC1 to the PI3P-specific
FYVE domain of EEA1, which targets TORC1 to endosomes,47
and still observed mCherry-Sch91–183 in dots (Figure 5H). In
turn, we also expressed mCherry-Sch91–183 in a strain express-
ing Tor1 with three internal GFP-tags, which due to its tagging
is found exclusively at the vacuole.44,47,58 Here, mCherry-
Sch91–183 was to a large extent lost from membranes similar to
its localization in the fab16A mutant (Figure 5I). These data indi-
cate that endosomal TORC1 is required to maintain a pool of
active Fab1 kinase at signaling endosomes, although we do
not exclude the possibility that TORC1 regulates Fab1 at the vac-
uole as well.
Given that TORC1 has multiple targets apart from Fab1 at the
signaling endosome and vacuole, we asked if inactivation of
TORC1 reverses the aberrant vacuole morphology of the
fab16D mutant. We therefore monitored the vacuole morphology
of wild-type and fab1 mutant cells after addition of rapamycin
(Figure S2B). Whereas wild-type and the fab16A mutant cells
did not show any change in their vacuole morphology, vacuoles
of the fab16D mutant became less fragmented (Figures S2B and
S2C). This indicates that the vacuole morphology observed in
the Fab1 mutant cells is caused by active TORC1.
In summary, we observe that TORC1-mediated phosphoryla-
tion of Fab1 causes re-localization of a pool of Fab1 and subse-
quent local PI(3,5)P2 synthesis at signaling endosomes.
Phosphorylation of Fab1 Determines Its FYVE-
Dependent Localization
How could phosphorylation alter the localization of Fab1?
Intriguingly, the identified TORC1 phosphorylation sites (S204,
206, 208) are just 20 residues upstream of the FYVE domain of
Fab1, a known PI3P interacting domain, which is localized
in Fab1 between residues 230 and 320. To test if phosphoryla-
tion targets Fab1 via its FYVE domain to PI3P positive
endosomes, we deleted the N-terminal 211 residues preceding
the FYVE domain. Surprisingly, the fab1D1–211 then behaved
like the fab16D mutant. Cells had multiple fragmented vacuoles
(Figure 6A), Fab1D1–211-positive dots colocalized with Vps8-pos-
itive endosomes (Figure 6A), and cells were sensitive to rapamy-
cin (Figure 6C). More Fab1 dots were found in fab16D and
Fab1D1–211 mutant (Figure 6B). In agreement, the isolated Fab1
FYVE domain interacted specifically with liposomes carrying
PI3P, though not as tightly as the isolated PX-domain of the
SNARE Vam7 (Figure 6D).
To better understand the N-terminal part of Fab1, we con-
structed further truncation mutants. Deletions of the first 50 or
100 residues did not affect Fab1 localization and function (Fig-
ure S3A and S3B). However, cells expressing Fab1 alleles that
were N-terminally truncated for 150 and 190 residues were as
sensitive to rapamycin as fab1D1–211 cells (Figure S3B). This304 Current Biology 31, 297–309, January 25, 2021suggests that phosphorylation may relieve an autoinhibition of
the FYVE domain and allow its binding to endosomal PI3P. In
support of this model, a minimal fragment of the first 330 resi-
dues of Fab1 localized to Ivy1-positive endosomes when car-
rying the phosphomimetic Fab16D mutations but was found on
vacuoles when carrying the Fab16A mutations (Figure S3C).
Interestingly, a Fab1 mutant lacking the entire N-terminal part
including the FYVE domain, fab1D1–320, appeared cytosolic, yet
grew like wild type on rapamycin (Figure S3B). This suggests
that residual targeting of Fab1 to the vacuole does not require
interaction with PI3P, yet may rely on another binding partner
on vacuoles. In agreement, cells expressing a point mutant in
Fab1 that inactivates the FYVE domain have a slight reduction
in cellular PI(3,5)P2 levels and wild-type-like vacuoles, but the
mutant Fab1 allele appeared also cytosolic.11
Overall, these data show that TORC1-mediated phosphoryla-
tion targets a pool of Fab1 via its FYVE domain to endosomes.
Phosphorylated Fab1 then generates a local pool of PI(3,5)P2
at signaling endosomes, which in turn recruits more TORC1,
and possibly other proteins (Figure S4). Upon fusion of signaling
endosomes with vacuoles, the local pool of PI(3,5)P2 may be
diluted out and TORC1 and Fab1 may get separated to permit
Fab1 dephosphorylation. This circuit may ultimately control
both endosomal and vacuolar membrane homeostasis and
signaling.
DISCUSSION
This study sheds light on the enigmatic crosstalk
between the metabolically regulated TORC1 and the conserved
Fab1 lipid kinase complex, which generates the low-abundant
lipid PI(3,5)P2.
1,7 In the past, a number of studies unraveled
the regulation of Fab1 during osmotic stress, which results in a
rapid synthesis of PI(3,5)P2 and subsequent vacuole
fragmentation.11,13,15,16,19,30,59,60 Here, we uncovered that
TORC1 phosphorylates Fab1, which in turn controls TORC1 ac-
tivity. Phosphorylation of Fab1 results in its preferential shift to
signaling endosomes, which also accumulate the EGO complex,
TORC1, and Ivy1. These structures have been coined vacuolar
microdomains in the past,49,61 yet are clearly endosomes (Fig-
ure 1),47 which lack the ESCRT-III-releasing Vps4 ATPase—as
shown here—and thus differ fromMVBs. Our data are consistent
with the idea that the lipid kinase Fab1 and TORC1 are counter-
regulated in space and activity.
We identify an N-terminal part of Fab1, which precedes the
PI3P interacting FYVE domain, as a regulator of the Fab1 local-
ization to vacuoles or endosomes. If the N-terminal segment is
missing or phosphorylated, Fab1 is found primarily at the
signaling endosome. We hypothesize that the FYVE domain
is somehow blocked by the N-terminal segment, possibly by
folding back to the FYVE domain, creating an autoinhibition.
TORC1-mediated phosphorylation of Fab1 could then relieve
this block and enable the Fab1 FYVE domain to efficiently
bind PI3P at the signaling endosome (Figure S4), a model
that requires further testing. Importantly, we observed that
signaling endosomes are the main organelles presenting
PI(3,5)P2 on their surface, and this lipid may be delivered by




Figure 6. Regulation of Fab1 Targeting to Endosomes by Its FYVE Domain
(A and B) Localization of Fab1 alleles relative to endosomes and vacuoles. The CORVET subunit Vps8 was tagged with mKATE in the indicated strains carrying
C-terminally mNEON Green-tagged Fab1. Vacuoles were stained with CMAC. Arrows indicate endosomes. (A) Scale bar, 5 mm. Quantification of dot-like
structures is shown in (B). Scale bar, 5 mm. At least 100 cells were counted in three independent experiments. Results are means ± SD. Significance was
determined with a two-tailed Student’s t test (***p < 0.001; ****p < 0.0001).
(C) Growth of wild-type, tor1D, and indicated fab1 mutant strains on rapamycin-containing plates. Spotting of cells was done as before (see Figure 5). wt, wild-
type.
(D) Interaction of the Fab1 FYVE domain with liposomes. Liposomes carrying 1mol% of PI3P, PI(3,5)P2, or no PIs were incubated with purified PX domain of Vam7
or the Fab1 FYVE domain (residues 230–320), and then separated by centrifugation into pellet and supernatant fraction (see STAR Methods). Proteins were
precipitated by TCA, resolved in sample buffer, and analyzed by SDS-PAGE and Coomassie staining.
See also Figures S3 and S4.
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been challenging as their enzymatic product, PI(3,5)P2, is a crit-
ical lipid for endosome and vacuole/lysosome biogenesis and
cellular physiology. Fab1 activity is tightly regulated by intramo-
lecular inhibition,62 which is relieved in hyperactive alleles15,59 or
by cyclin-dependent kinases (i.e., Pho80/8563). Yet, these data
could not explain why Fab1 deletions have such an impact on
endosomal biogenesis if Fab1 is primarily present on vacuoles.21
We now consider it likely that this observation is due to an indi-
rect effect on vacuole and endosome biogenesis as PI(3,5)P2
has multiple effectors at both organelles, including TORC1.
PI(3,5)P2 recruits TORC1 to vacuoles,
31 and, as we show here,
also to signaling endosomes. Specifically, we found TORC1, the
TORC1-regulating EGO complex, Ivy1, and Fab1 shift from their
primary localization at vacuoles to signaling endosomes in cells
expressing the phosphomimetic fab16D mutant allele. In such
cells, TORC1 activity is significantly reduced on both endo-
somes and vacuoles and was as reduced as in tor1D cells. At
the vacuole, reduced TORC1 activity could be due to the phys-
ical separation of TORC1 from its vacuolar target Sch9. It is
also possible that a local excess of PI(3,5)P2, as observed in
the fab16Dmutant at signaling endosomes, triggers the formation
of inactive TORC1multimers.44,45 In an intriguing analogy, PI(4,5)
P2 is necessary for TORC2membrane localization,
64 but sponta-
neous phase separation of PI(4,5)P2 into plasma membrane do-
mains sequesters and inactivates TORC2, perhaps also by fa-
voring the formation of inactive TORC2 multimers.65,66
We speculate that the lipid kinase and PI3P effector Fab1 and
the PI(3,5)P2 effector TORC1 sense and co-regulate the balance
between PI3P and PI(3,5)P2 at endosomes and at the vacuole.
The respective balance of these lipids may locally define the
membrane positioning of TORC1 relative to its regulator(s)such as Pib2, which binds PI3P.40,42,43,45 In addition, the balance
between PI3P and PI(3,5)P2 is likely important for the activity of
other PI3P and PI(3,5)P2 effectors on the vacuole such as the
V-ATPase or Atg18.17,29,30,67
Howcould Fab1 and TORC1 sense and regulate the balance be-
tween PI3P and PI(3,5)P2 at endosomes or vacuoles?We propose
that the FYVE domain of Fab1 combines two functions: on the one
hand, it serves as a sensor for PI3P levels. On the other hand, it
functions as a targeting module, which is co-regulated by
TORC1-mediated phosphorylation of a stretch of amino acids
that is located in its immediate proximity in the N-terminal part of
Fab1 (Figure S4). If this stretch is not phosphorylated, it likely
auto-inhibits the FYVE domain, which causes Fab1 to primarily
localize to the vacuole (Figure S4). On the vacuolar membrane,
Fab1 changes the PI3P to PI(3,5)P2 ratio by consuming PI3P and
generating PI(3,5)P2, which results in enhanced recruitment of
TORC1 to the vacuole.
Depending on its metabolic activation state, which is
controlled by nutrient cues such as amino acids, TORC1 can
then phosphorylate Fab1 proximal to its FYVE domain and
thereby release the FYVE domain from autoinhibition (Figure S4).
This would then allow the FYVE domain to bind PI3P and conse-
quently favor a redistribution of Fab1 to the signaling endosome,
where Fab1 can generate PI(3,5)P2. In turn, increasing PI(3,5)P2
will trigger the recruitment of TORC1 to signaling endosomes
and hence sequester TORC1 away from its vacuolar targets (Fig-
ure S4). As long as TORC1 receives metabolic inputs at signaling
endosomes, it will then be able to keep Fab1 phosphorylated in a
positive feedback loop. It is likely that phosphorylation of other
TORC1 targets is likewise promoted by phosphorylated Fab1
at the signaling endosome and vacuole,46 which may maintain
their identity.Current Biology 31, 297–309, January 25, 2021 305
ll
OPEN ACCESS ArticleRe-localization of Fab1 to the vacuole (Figure S4) may occur
as a results of any of several possible events that are not neces-
sarily mutually exclusive: (1) if TORC1 receives diminished meta-
bolic inputs at the signaling endosome, the autoinhibitory stretch
of Fab1 may be preferentially dephosphorylated; (2) Fab1 may
consume themajority of the PI3Pmolecules present on signaling
endosomes, thus running out of substrate to associate with; (3)
Fab1 is actively dephosphorylated by a yet to be identified phos-
phatase; or (4) signaling endosomes fuse with vacuoles, thus
diluting out PI3P and PI(3,5)P2, separating TORC1 from Fab1,
and favoring dephosphorylation of Fab1 as illustrated (Figure S4).
In either of these scenarios, Fab1 and TORC1 cooperate in a
finely tuned balance. This balance can be affected by superim-
posed metabolic or osmotic stress control mechanism, which
may even differ at the signaling endosome and at the vacuole.
In sum, we hypothesize that it is exactly this—the PI3P to
PI(3,5)P2 ratio at each organelle—that determines the intimate
crosstalk between Fab1 and TORC1.
There are, of course, several open questions. It is intriguing
that the PI(3,5)P2 phosphatase Fig4 is part of the Fab1 complex
and could also be involved in counterbalancing the Fab1-medi-
ated PI(3,5)P2 synthesis at signaling endosomes or at vacuoles.
In addition, the supply routes of PI3P to vacuoles and signaling
endosomes likely differ. Vacuoles may receive their PI3P mainly
via MVBs, whereas signaling endosomes may perhaps receive
PI3P mostly during their biogenesis. Finally, our model may be
extended to other vacuolar PI(3,5)P2 effectors, which could be
tuned to recognize fine-grained alterations in the respective
phosphoinositide levels.
Our model is congruent and supported by all of our observa-
tions and compatible with findings of many others in the field.
We also suspect that a similar crosstalk extends to metazoans,
where the Fab1 homolog PIKfyve also has been linked to
mTORC1 activity.1,22–24 Whether this crosstalk also occurs in
metazoans, as shown here for yeast Fab1 and TORC1, is an
attractive hypothesis that remains to be evaluated. Intriguingly,
the Raptor subunit of mTORC1 also binds PI(3,5)P2, and PIKfyve
depletion strongly affects mTORC1 localization in adipocytes.23
However, PIKfyve depletion has drastic pleiotropic effects on the
endolysosomal system. The analysis of a possible mTORC1 and
PIKfyve crosstalk will thus require more targeted mutant studies
in the future.
PI(3,5)P2 levels are crucial for the correct function of lyso-
somes, and mutations in subunits of the Fab complex result in
neurodegenerative diseases in humans.25–28 We believe that
our novel insights into Fab1-regulation will provide a fresh view
on how to understand the origin of these diseases.STAR+METHODS
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CHAPS Carl Roth GmbH Art.Nr. 149.2
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Tris PanReac AppliChem ITW Reagents A1379; CAS:
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Glycerol Carl Roth GmbH Art. No. 7530.4
CAS: 56-81-5
Imidazole Carl Roth GmbH Art. No. X998.4
CAS: 288-32-4
CSM(powder) MP Biomedicals SKU: 114500022
CSM-Ura(powder) MP Biomedicals SKU 114511212
18:1 (D9-Cis) PC (DOPC) Avanti Polar Lipids SKU: 850375P
18:1 (D9-Cis) PE (DOPE) Avanti Polar Lipids SKU: 850725P
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PI(3)P diC16 Echelon Bioscience SKU: P-3016-
PI(3,5)P2 diC16 Echelon Bioscience SKU: P-3516-
ATTO-DPPE dye ATTO-TEC AD550-151
CellTracker Blue CMAC Dye Invitrogen Cat#C2110
FM 4-64 Dye Invitrogen Cat#T3166
Coomassie Brilliant blue G-250 PanReac AppliChem ITW Reagents A3480; CAS:
6104-58-1
Glutathione Sepharose 4B Merck SKU: GE17-0756-01
Protino Ni-NTA Agarose Macherey-Nagel CAS: 64-17-5
Dynabeads M-270 Epoxy Thermo Fisher Cat#14304
[g-32P]-ATP Hartmann Analytic Cat#SRP-501
Sypro Ruby Protein Gel Stain Merck Cat#S4942
Arg10 Cambridge Isotope Laboratories CNLM-539-H
Lys8 Cambridge Isotope Laboratories CNLM-291-H
10kD MW-cutoff filters PALL OD030C34
Titanium dioxide GL Sciences 5020-75010
Critical Commercial Assays
NucleoSpin Gel and PCR Clean-up Macherey-Nagel REF 740609.250
GeneJET Plasmid-Miniprep-Kit Thermo Fisher Scientific Cat#K0503
Experimental Models: Cell Lines
S. cerevisiae: Strain background: BY4741 Brachmann et al.69 N/A
S. cerevisiae: Strain background: BY4727 Brachmann et al.69 N/A
Experimental Models: Organisms/Strains
CUY518: MATa; his3D1, leu2D0, met15D0, ura3D0
tor1D::KanMX
Heitman et al.70 N/A
CUY10936: MATa; his3D1, leu2D0, met15D0, ura3D0
FAB1::mNeonGreen::hphNT1
This study N/A
CUY11107: MATa ; his3D200 leu2D0 lys2D0 met15D0
trp1D63 ura3D0 FAB1::VC::KanMX
This study N/A




CUY11260: MATa ; his3D200 leu2D0 lys2D0 met15D0
trp1D63 ura3D0 FAB1::VC::KanMX TRP1::CET1pr-
VN::KOG1
This study N/A
CUY11579: MATa; his3D1, leu2D0, met15D0, ura3D0
FAB1::mNeonGreen::hphNT1 VPS8::mKate::ClonNAT
This study N/A
CUY11710: MATa; his3D1, leu2D0, met15D0, ura3D0
IVY1::GFP::hphNT1 VPS8:: mKate::ClonNAT
This study N/A
CUY11845: MATa ; his3D200 leu2D0 lys2D0 met15D0
trp1D63 ura3D0 FAB1::VC::Kan MXTRP1::CET1pr-
VN::KOG1 VPS8::mkate::ClonNAT
This study N/A
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CUY12077: MATa; his3D1, leu2D0, met15D0, ura3D0
fab1S202A/S203A/S204A/T206A/S208A/S210A
This study N/A
CUY12078: MATa; his3D1, leu2D0, met15D0, ura3D0
fab1 S202D/S203D/S204D/T206D/S208D/S210D
This study N/A
















CUY12227: MATa; his3D1, leu2D0, met15D0, ura3D0
IVY1::mGFP-hphNT1 VPS4::3xHA-mCherrry-KanMX
This study N/A
CUY12259: MATa; his3D1, leu2D0, met15D0,
ura3D0 URA3::PHO5pr-GFP::FAB1
This study N/A
CUY12260: MATa; his3D1, leu2D0, met15D0, ura3D0
URA3::PHO5pr-GFP::FAB1-211aa-end
This study N/A


























CUY12362: MATa; his3D1, leu2D0, met15D0,
ura3D0 URA::PHO5pr-GFP-FAB1-151aa-end
This study N/A
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CUY12365: MATa; his3D1, leu2D0, met15D0,
ura3D0 URA::PHO5pr-GFP-FAB1-191aa-end
This study N/A
CUY12367: MATa; his3D1, leu2D0, met15D0,
ura3D0 URA::PHO5pr-GFP-FAB1-321aa-end
This study N/A
CUY12445: MATa; his3D1, leu2D0, met15D0,
ura3D0 URA::PHO5pr-GFP-FAB1-51aa-end
This study N/A
CUY12446: MATa; his3D1, leu2D0, met15D0,
ura3D0 URA::PHO5pr-GFP-FAB1-101aa-end
This study N/A
CUY12650: MATa his3D1 leu2D0 met15D0 ura3D0
IVY1::mGFP-hphNT1 KOG1::CloNAT-ADHpr
This study N/A












CUY12656: MATalpha his3D200 leu2D0 lys2D0
met15D0 trp1D63 ura3D0 FAB1::VC-KanMX TRP1-
CET1pr-VN::KOG1 IVY1::mkate-natNT2
This study N/A
YL516: MATa ; his3D1, leu2D0, ura3D0 Binda et al.71 N/A
RKH395: MATa ; his3D1, leu2D0, ura3D0 LEU2::GFP-
TOR1
Horvath et al.68 N/A
RKH486: MATa ; leu2D0, ura3D0 his3D1::GFP-
SCH91-183::SpHIS5
This study N/A
RKH488: MATa ; leu2D0, ura3D0 his3D1::GFP-
SCH91-183::SpHIS5 fab1D::KanMX
This study N/A
RKH490: MATa ; leu2D0, ura3D0 his3D1::GFP-
SCH91-183::SpHIS5 vac7D::KanMX
This study N/A
RKH492: MATa ; leu2D0, ura3D0 his3D1::GFP-
SCH91-183::SpHIS5 vac14D::KanMX
This study N/A
RKH555: MATa ; leu2D0, ura3D0 his3D1::GFP-
SCH91-183::SpHIS5 atg18D::KanMX
This study N/A
RKH478: MATa ; his3D1, leu2D0, ura3D0 tor1D::
hphNT1 trp1D::KanMX
This study N/A
MP52-2A: MATa ; his3D1, leu2D0, ura3D0
tor1D330-3GFP
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Recombinant DNA
GST-p40-PX Takatori et al.72 N/A
pRS315: CEN/ARS, LEU2 Sikorski and Hieter73 N/A
pRS413: CEN/ARS, HIS3 Sikorski and Hieter73 N/A
pRS414: CEN/ARS, TRP1 Sikorski and Hieter73 N/A
pRS415: CEN/ARS, LEU2 Sikorski and Hieter73 N/A
pRS416: CEN/ARS, URA3 Sikorski and Hieter73 N/A
p1379: CEN/ARS, URA3, MET15 Hatakeyama and De Virgilio46 N/A
p1770: CEN/ARS, HIS3, MET15 Varlakhanova et al.51 N/A
CU1776: CEN/ARS, URA3, GFP-CPS1 Odorizzi et al.21 N/A









CU5263: CEN/ARS, URA3, Pnop1-FAB1-1-330aa-GFP This study N/A
pRCC-K: 2m, KanMX, Cas9 Generoso et al.74 N/A
CU5048: 2m, KanMX, Cas9, Fab1-near-203aa This study N/A
p2976: 2m, URA3, PPRC1-SCH9
709-824-GFP-PHO81-63 Hatakeyama and De Virgilio46 N/A
p3608: CEN/ARS, HIS3, PVAC8-yEmRFP-TOR1 This study N/A




p3693: CEN/ARS, HIS3, PADH1-GFP-SCH9
1-183 This study N/A
p3694: CEN/ARS, HIS3, PADH1-GFP-
SCH9184-397
This study N/A
p3695: CEN/ARS, HIS3, PADH1-GFP-SCH9
1-397 This study N/A
p3715: CEN/ARS, HIS3, PADH1-yEmRFP-SCH9
1-183 This study N/A
p3745: CEN/ARS, HIS3, PCYC1-yEmRFP-SCH9
1-183 This study N/A
p3776: CEN/ARS, LEU2, PCYC1-GFP-
SCH91-183
This study N/A
pRH3488: [pET-28a (+)]-His6-fab1 (1-600) (codon
optimized)
This study N/A
pRH3490: [pET-28a (+)]-His6-fab1 (580-1180) (codon
optimized)
This study N/A
pRH3491: [pET-28a (+)]-His6-fab1 (1160-1760) (codon
optimized)
This study N/A





(1-600) (3A) (codon optimized)
This study N/A
pMP3669: [pET-28a (+)]-His6-
fab1 S203A/ S204A/ T206A/ S208A/ S210A (1-600)
(5A) (codon optimized)
This study N/A
p2981: 2m, HIS3, PVAC8-EEA1(human)
1257-1411-GFP-
SCH9709-824
Hatakeyama and De Virgilio46 N/A
p3047: 2m, LEU2, PPRC1-SCH9
709-824-GFP-PHO81-63 Hatakeyama and De Virgilio46 N/A
pJU793: CEN/ARS, URA3, GFP-SCH9 Urban et al.53 N/A
p3296: CEN/ARS, URA3, GFP-SCH9D1-183 This study N/A
p3297: CEN/ARS, URA3, GFP-SCH9D184-397 This study N/A
(Continued on next page)
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REAGENT or RESOURCE SOURCE IDENTIFIER
p3298: CEN/ARS, URA3, GFP-SCH9D1-397 This study N/A
p3898: [pET-24D]-GST-SCH91-183-His6 This study N/A
pCDF-GP(GST-PreScission)-Fab1-220-330aa This study N/A
Software and Algorithms
Fiji National Institutes of Health https://imagej.net/Fiji/Downloads
Adobe Photoshop CS4 Adobe Inc. N/A
Microsoft Excel Microsoft Inc. N/A




Further information and requests for resource and regents should be directed to and will be fulfilled by the Lead Contact, Christian
Ungermann (cu@uos.de).
Materials Availability
Yeast strains and plasmids generated in this study are available on request.
Data and Code Availability
The published article includes all datasets generated or analyzed during this study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Yeast strains, plasmids, and media
Yeast strains and plasmids are listed in Key Resource table. Yeast strains were grown in yeast extract peptone dextrose (YPD) con-
taining 1% yeast extract, 2% peptone and 2% glucose at 30C for most growth analyses. For microscopy experiments and spotting
assays, yeast strains were grown in synthetic dextrose complete (SDC) media, which contained 6.75 g yeast nitrogen base without
amino acids, 20 g glucose, and 0.8 g complete supplement media (CSM) powder per liter.
METHOD DETAILS
Yeast genetic manipulation and molecular biology
S. cerevisiae strains used are listed in Resource Table. Geneticmanipulations weremade by homologous recombination of PCR frag-
ments as described previously.75,76 Yeast cells were grown in YPD medium overnight and then diluted to 0.1 OD600. They were then
grown to log-phase, washed with sterile water, and then with 0.1 M lithium acetate. Cells were resuspended in 350 ml 0.1 M lithium
acetate, and 50 ml were used for transformation. The transformation mix contains 240 ml 50% PEG, 36 ml 1 M lithium acetate, 25 ml
carrier DNA and 50 ml cells. Themix was incubated at 42C for 45min and cells were then plated on selection plates. A CRISPR-Cas9
approachwas selected to generate FAB1 pointmutants.74 For generation of the corresponding Cas9 plasmid (CU5048), the following
primers were used: Fw-GGACAGGGATGCGGTCAACGAAGAAGgttttagagctagaaatagcaagttaaaataagg, Rv- CTTCTTCGTTGACCG
CATCCCTGTCCgatcatttatctttcactgcggag. We transform both plasmid (CU5048) and the corresponding single stranded DNA
(ssDNA) templates for homology directed repair (HDR), HDR-Fab16A TAAAATGCGAACAGGAAACTCTTGGcCAGGGcTGCGGcC
AACGcAGcAGcGGCACTCTTTATCGAAGACACTTCATCGCC) or HDR-Fab16D (TAAAATGCGAACAGGAAACTCTTGtcCAGGtcTGC
GtcCAAatcAtcAtcGGCACTCTTTATCGAAGACACTTCATCGCC), into the used background strains. After transformation, the cells
were re-suspended in YPD and grown at 30C for 1-2 h for recovery before cells were placed onto plates containing G418. Clones
containing the correct mutations were identified by sequencing of the FAB1 region. All plasmids are listed in Resource Table.
Light microscopy and image analysis
Cells were grown to log-phase in yeast extract peptone (YP) medium containing glucose (YPD), or synthetic medium supplemented
with essential amino acids (SDC). Vacuole membrane was stained with 30 mMFM4-64 for 30 min, followed by washing with medium,
and incubation in medium without dye for 1 h before analysis.77 For luminal staining of vacuoles, cells were incubated in 0.1 mM 7-
amino-4-chloromethylcoumarin (CMAC) for 10 min and washed with SDC medium. Images were acquired on an Olympus IX-71
inverted microscope equipped with a 100x NA 1.49 objective, a sCMOS camara (PCO), an InsightSSI illumination system and SOft-
WoRx software (Applied Precision). Images were processed with ImageJ. One representative plane of a z stack is shown unless
noted. For quantifications the number of vacuoles were counted in three independent experiments and at least 100 cells wereCurrent Biology 31, 297–309.e1–e8, January 25, 2021 e6
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of colocalizating dots.
Growth test
Cells were grown to log-phase, washed twice with SDC, and diluted to an optical density 600 (OD600) of 0.25. Serial dilutions (1:10)
were spotted onto plates and imaged after 2-4 days.
In vivo local TORC1 activity assay
Endosomal and vacuolar TORC1 activities were assayed as previously described.47 The C-terminal portion of Sch9, an established
TORC1 substrate, was fused to GFP and an organelle targeting domain: FYVE domain of human EEA1 protein for the endosomal
reporter (ET) or the N-terminal domain of Pho8 vacuolar phosphatase for the vacuolar reporter (VT). The strains were transformed
with ET/VT reporters and their phosphorylation levels in cell lysate was assessed by western blotting using the phosphospecific
anti-Sch9-pThr737 antibodies.
In vitro kinase assay of Fab1 fragments with purified TORC1
In vitro kinase assays were performed, with some variation, essentially as described.78 TORC1 was purified from a Tco89-TEV-TAP-
expressing yeast strain grown in YPD and treated for 10minwith cycloheximide. The cells were collected by filtration, rapidly frozen in
liquid nitrogen, and subjected to cryogenic disruption with an MM 400Mixer Mill (Retsch). The obtained powder was resuspended in
extraction buffer (50 mM HEPES/NaOH, pH 7.5, 5 mM CHAPS, 400 mM NaCl, 1 mM EDTA, 0.5 mM DTT, 400 mM Pefabloc, Roche
complete protease inhibitor EDTA-free). The cleared lysate was incubated with IgG-coupled Dynabeads (Dynabeads M-270 Epoxy;
Invitrogen) for 2 h at 4C. After 5 washes with wash buffer (50 mMHEPES/NaOH [pH 7.5], 5 mMCHAPS, 400 mMNaCl, 0.5 mMDTT)
the TORC1 complex was eluted using 2% TEV protease and stored at 80C after addition of 10% glycerol.
Recombinant His6-tagged Fab1 variants were expressed in Rosetta E. coli cells. Bacterial cells were disrupted by sonication in
lysis buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 10 mM Imidazole, Roche complete protease inhibitor EDTA-free, 0.1%
NP40) and proteins were purified through binding to Ni-NTA agarose beads (wash buffer containing 50 mM NaH2PO4, pH 8.0,
300 mM NaCl, 20 mM Imidazole; elution buffer containing 50 mM NaH2PO4, pH 8.0, 300 mM NaCl, 250 mM Imidazole). Eluted frac-
tions were dialysed into 50 mM HEPES, pH 7.5, 150 mM NaCl, 5% glycerol (Slide-A-Lyzer MINI Dialysis Device, 10K MWCO).
In vitro kinase reactions were performed in kinase buffer (50mMHEPES/NaOH, pH 7.5, 150mMNaCl), with 120 ng of purified His6-
Fab1 variants and TORC1 (containing 60 ng Tor1) in 30 ml total volume, started by adding the ATP mix (4.2 mMMgCl2, 300 mM ATP,
and 3.3 mCi [g-32P]-ATP [Hartmann Analytic, SRP-501]), and stopped by adding SDS-PAGE sample buffer. Proteins were separated
by SDS-PAGE, stained with Sypro Ruby (Sigma) to assess loading, and analyzed using a phosphorimager (Typhoon FLA 9500; GE
Healthcare).
Purification of recombinant Sch91-183-His6
GST-Sch91-183-His6, which has a TEV protease cleavage site between the GST and Sch9
1-183, was purified from bacteria (Rosetta
strain). Expression was induced by 0.5 mM IPTG overnight at 18C. Cells were lysed by sonication in lysis buffer (200 mM NaCl,
50 mM Tris-HCl [pH 7.5], 5% glycerol, 1 mM DTT, Roche protease inhibitor cocktail) and clarified by centrifugation. The protein
was purified by incubation with glutathione Sepharose beads for 1 h at 4C, and washed with lysis buffer. Sch91-183-His6 was eluted
by incubating the beads with TEV protease in cleavage buffer (50 mM Tris-HCl [pH 7.5], 0.5 mM EDTA, 1 mM DTT) for 1 h at 30C.
Liposome sedimentation assay
Liposomes were prepared as previously described79 with modifications. Liposomes were generated from the lipid mixtures (81.5mol
% dioleoylphosphatidylcholine [Avanti Polar Lipids 850375], 18 mol% dioleoylphosphatidylethanolamine, 0.5 mol% Atto dye [ATTO-
TEC AD550-151]) with or without PI(3,5)P2 or PI3P at the indicated concentrations. The lipids were dried by evaporation for 1 h and
dissolved in 1 mL of assay buffer (20 mM PIPES-KOH [pH 6.5], 120 mM KCl) supplemented with 5% w/v sucrose to a final lipid con-
centration of 2mM. The liposome suspension was freeze/thawed for 8 times in liquid nitrogen and at 55C, respectively. For the bind-
ing assay, 0.5 mg of Sch91-183-His6 was pre-cleaned in assay buffer by centrifugation at 20,000 g for 20 min at 4
C. The supernatant
containing Sch91-183-His6 was mixed with 0.54 mM (final concentration) liposomes and incubated at room temperature for 15 min.
The liposomes were then centrifuged (20,000 g for 20 min at 4C), and the supernatant (unbound fraction) was separated from the
pellet (liposome-bound fraction). Samples were TCA-precipitated and analyzed via SDS-PAGE and subsequent immunoblot analysis
using the anti-His Tag antibodies (SIGMA-ALDRICH, Germany).
Mass spectrometry sample preparation and data analysis
MSsampleswere basically generated as described.47 Briefly, for in vivo analyses yeast strainswere grown in SILACmediumcontaining
non-labeled or labeled arginine and lysine variants, L-arginine-13C6-
15N4 (Arg10) and L-lysine-
13C6-
15N2 (Lys8) (Sigma-Aldrich). Cells
were treated or not with 200 ng/mL rapamycin for 30 min, and trichloroacetic acid (TCA)-treated cell pellets (50 mg) of both labels
were mixed, and stored at 80C for further use. For in vitro analyses, purified TORC1 was incubated with the Fab1 (1-600) fragment
in thepresenceof 1mMMnCl2 for 30min asdescribedabove.Asa negativecontrol, purifiedTORC1was inhibitedwith 6mMwortmannin
for 30 min. In vitro kinase assays of purified Fab1 variants and TORC1 were performed on 10 kDMW-cutoff filters (Pall) as described.47e7 Current Biology 31, 297–309.e1–e8, January 25, 2021
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h, in case of in vivo analyses, and trypsin (Promega) overnight. Phosphopeptides were enriched by TiO2 beads (GL Sciences) essen-
tially as described80 and analyzed by LC-MS/MS using a QExactive HF-X mass spectrometer coupled to an EasyLC 1200 nanoflow-
HPLC (Thermo Scientific). MS raw files were analyzed using MaxQuant (version 1.6.2.10),81 and a Uniprot full-length S.cerevisiae
database (March, 2016) containing common contaminants such as keratins and enzymes used for in-gel digestion. Fixed modifica-
tion was carbamidomethylcysteine, variable modifications were protein amino-terminal acetylation, serine-, threonine- and tyrosine-
phosphorylation, and oxidation of methionine. The MS/MS tolerance was set to 20 ppm and three missed cleavages were allowed
using trypsin/P as enzyme specificity. Peptide, site, and protein FDR based on a forward-reverse database were set to 0.01, mini-
mum peptide length was set to 7, the minimum score for modified peptides was 40, and minimum number of peptides for identifi-
cation of proteins was set to one, which must be unique. MaxQuant results were analyzed using Perseus.82
QUANTIFICATION AND STATISTICAL ANALYSIS
Co-localization between two proteins
The number of co-localizing dot-like structure between Fab1 and other proteins (Figures 1C and 3), or Ivy1 (Figure 1A) and other pro-
teins were counted, which were divided by the total numbers of the Fab1 dot-like or Ivy1 dot-like signal. For statistical analysis, two-
tailed, unpaired Student’s t tests were used, and data is presented as mean + SD.
Vacuole numbers
The number of the cell containing different amounts of vacuoles was counted in Fab1 mutants (Figure 3B). Two-tailed, unpaired Stu-
dent’s t tests were used, and data is presented as mean ± SD.
Dots structures in cells
The number of dot-like signals for each protein were counted per 100 cells, and the results are shown as graphs (Figures 3H and 6B).
Two-tailed, unpaired Student’s t tests were used, and data is presented asmean + SD. The number of cells containing Sch91-183 dots
were counted and the relative distribution is shown in Figure 5H (no comparative statistical analysis was performed here) and Figures
5G and 5I (Two-tailed, unpaired Student’s t tests were used for statistical analysis).
Western blot
Western blot bands were analyzed by ImageJ, and the quantities were calculated from the relative intensities. For statistical analysis,
two-tailed, unpaired Student’s t tests were used, and data is presented as mean + SD.Current Biology 31, 297–309.e1–e8, January 25, 2021 e8
